Two Sigma Advisers’s Accendra Health ACH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-542,472
| Closed | -$1.52M | – | 1494 |
|
|
2025
Q4 | $1.52M | Buy |
542,472
+89,500
| +20% | +$320K | ﹤0.01% | 1293 |
|
|
2025
Q3 | $2.17M | Buy |
452,972
+65,700
| +17% | +$418K | ﹤0.01% | 1114 |
|
|
2025
Q2 | $3.52M | Buy |
387,272
+228,600
| +144% | +$1.68M | 0.01% | 872 |
|
|
2025
Q1 | $1.43M | Buy |
158,672
+90,000
| +131% | +$950K | ﹤0.01% | 1289 |
|
|
2024
Q4 | $898K | Sell |
68,672
-42,600
| -38% | -$568K | ﹤0.01% | 1515 |
|
|
2024
Q3 | $1.75M | Sell |
111,272
-56,400
| -34% | -$854K | ﹤0.01% | 1144 |
|
|
2024
Q2 | $2.26M | Sell |
167,672
-182,300
| -52% | -$3.73M | 0.01% | 1122 |
|
|
2024
Q1 | $9.7M | Sell |
349,972
-120,300
| -26% | -$2.67M | 0.02% | 547 |
|
|
2023
Q4 | $9.06M | Buy |
470,272
+117,100
| +33% | +$2.12M | 0.02% | 567 |
|
|
2023
Q3 | $5.71M | Buy |
353,172
+290,200
| +461% | +$5.15M | 0.01% | 667 |
|
|
2023
Q2 | $1.2M | Buy |
62,972
+34,300
| +120% | +$612K | ﹤0.01% | 1464 |
|
|
2023
Q1 | $417K | Buy |
+28,672
| New | +$514K | ﹤0.01% | 2011 |
|
|
2021
Q2 | – | Sell |
-21,972
| Closed | -$826K | – | 2620 |
|
|
2021
Q1 | $826K | Sell |
21,972
-149,200
| -87% | -$4.67M | ﹤0.01% | 1752 |
|
|
2020
Q4 | $4.63M | Sell |
171,172
-47,700
| -22% | -$1.23M | 0.01% | 855 |
|
|
2020
Q3 | $5.5M | Sell |
218,872
-9,900
| -4% | -$144K | 0.02% | 734 |
|
|
2020
Q2 | $1.74M | Sell |
228,772
-190,400
| -45% | -$1.39M | 0.01% | 1273 |
|
|
2020
Q1 | $3.83M | Sell |
419,172
-34,700
| -8% | -$209K | 0.01% | 816 |
|
|
2019
Q4 | $2.35M | Sell |
453,872
-131,800
| -23% | -$846K | 0.01% | 1154 |
|
|
2019
Q3 | $3.4M | Sell |
585,672
-160,200
| -21% | -$718K | 0.01% | 902 |
|
|
2019
Q2 | $2.39M | Buy |
745,872
+258,800
| +53% | +$883K | 0.01% | 1135 |
|
|
2019
Q1 | $2M | Buy |
487,072
+46,400
| +11% | +$293K | 0.01% | 1225 |
|
|
2018
Q4 | $2.79M | Sell |
440,672
-88,485
| -17% | -$919K | 0.01% | 1031 |
|
|
2018
Q3 | $8.74M | Sell |
529,157
-144,800
| -21% | -$2.46M | 0.02% | 633 |
|
|
2018
Q2 | $11.3M | Sell |
673,957
-2,100
| -0.3% | -$34K | 0.03% | 548 |
|
|
2018
Q1 | $10.5M | Sell |
676,057
-113,575
| -14% | -$2.03M | 0.03% | 565 |
|
|
2017
Q4 | $14.9M | Buy |
789,632
+618,747
| +362% | +$13.7M | 0.04% | 476 |
|
|
2017
Q3 | $4.99M | Sell |
170,885
-123,119
| -42% | -$3.64M | 0.01% | 793 |
|
|
2017
Q2 | $9.46M | Sell |
294,004
-113,053
| -28% | -$3.71M | 0.03% | 526 |
|
|
2017
Q1 | $14.1M | Buy |
407,057
+44,828
| +12% | +$1.6M | 0.05% | 465 |
|
|
2016
Q4 | $12.8M | Buy |
362,229
+66,257
| +22% | +$2.24M | 0.05% | 407 |
|
|
2016
Q3 | $10.3M | Buy |
295,972
+240,900
| +437% | +$8.43M | 0.04% | 416 |
|
|
2016
Q2 | $2.06M | Buy |
55,072
+39,172
| +246% | +$1.47M | 0.01% | 852 |
|
|
2016
Q1 | $643K | Buy |
15,900
+2,400
| +18% | +$89.4K | ﹤0.01% | 1350 |
|
|
2015
Q4 | $486K | Buy |
13,500
+1,000
| +8% | +$36.2K | ﹤0.01% | 1343 |
|
|
2015
Q3 | $399K | Buy |
+12,500
| New | +$426K | ﹤0.01% | 1378 |
|
|
2014
Q2 | – | Sell |
-9,372
| Closed | -$330K | – | 2628 |
|
|
2014
Q1 | $330K | Buy |
+9,372
| New | +$331K | ﹤0.01% | 1811 |
|
Other funds holding ACH
CCM
ICM
Two Sigma Advisers's ACH Position: Q1 2026 in Review
Two Sigma Advisers sold out of Accendra Health (ACH) in Q1 2026, closing a stake of 542,472 shares — an estimated $1.52M sold.
Two Sigma Advisers first reported a position in ACH in Q1 2014 and held it in 36 quarters. The position peaked at $14.9M in Q4 2017. 142 funds tracked by Wall St. Rank hold ACH as of Q1 2026.
- Two Sigma Advisers reported no remaining Accendra Health position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 542,472 Accendra Health shares in Q1 2026, an estimated $1.52M.
- Two Sigma Advisers first reported a position in Accendra Health in Q1 2014 and held it in 36 quarters.
- Two Sigma Advisers's Accendra Health position peaked at $14.9M in Q4 2017.
- 142 funds tracked by Wall St. Rank held Accendra Health as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.